Schedule Update - effective 1 March 2009 (text extract)

This is the text extract for Schedule Update - effective 1 March 2009, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 March 2009 Cumulative for January, February and March 2009 Section H cumulative for December 2008 and January, February and March 2009.

Contents

Summary of PHARMAC decisions effective 1 March 2009 ............................. 3 Simvastatin tender ........................................................................................ 5 Changes to prescriber restrictions for acitretin and isotretinoin .................... 5 New 5 second Optium blood glucose test strip ............................................. 6 Pantoprazole and Omeprazole injections ...................................................... 6 Nicotinell gum (nicotine replacement therapy) ............................................. 6 Discontinuation of Minulet and Triphasil ....................................................... 6 New antiretroviral prescriber ......................................................................... 7 Indomethacin discontinuation ...................................................................... 7 Octreotide ..................................................................................................... 7 Important information about diltiazem hydrochloride changes .................... 8 Tender News .................................................................................................. 9 Looking Forward ........................................................................................... 9 Sole Subsidised Supply products cumulative to March 2009....................... 10 New Listings ................................................................................................ 19 Changes to Restrictions ............................................................................... 21 Changes to Subsidy and Manufacturer’s Price............................................. 26 Changes to Brand Name ............................................................................. 31 Changes to Description ............................................................................... 31 Changes to General Rules............................................................................ 31 Changes to PSO........................................................................................... 32 Changes to Sole Subsidised Supply ............................................................. 32 Delisted Items ............................................................................................. 33 Items to be Delisted .................................................................................... 34 Section H changes to Part II ........................................................................ 38 Section H changes to Part IV ....................................................................... 42 Index ........................................................................................................... 43

Summary of PharmaC decisions

effeCtive 1 marCh 2009 New listings (pages 19 – 20) • Amoxycillin clavulanate (Synermox) tab 625 mg • Cilazapril (Inhibace) tab 2.5 mg and 5 mg – new pack size, 28 tab • Glucose dehydrogenase (Optium 5 second test) - 25 and 50 test OP • Ibuprofen (Ethics Ibuprofen) tab 200 mg • Mebendazole (DeWorm) tab 100mg – 24 tab pack • Omperazole (Dr Reddy’s Omeprazole) inj 40 mg - pack of 5 • Pantoprazole (Pantocid) inj 40 mg • Simvastatin (Arrow-Simva) tab 10 mg, 20 mg, 40 mg and 80 mg – 90 tab pack Changes to restrictions (pages 21 – 24) • Acitretin (Neotigason) cap 10 mg and 25 mg – removal of Specialist prescription and addition of Special Authority • Alendronate sodium (Fosamax) tab 70 mg (Fosamax Plus) tab 70 mg with cholecalciferol 2800 iu – amended Special Authority criteria • Alendronate sodium (Fosamax) tab 40 mg – amended Special Authority criteria • Auranofin (Ridaura) tab 3 mg – removal of Retail pharmacy–Specialist • Baclofen (Pacifen) tab 10 mg – removal of Retail pharmacy-Specialist • Calcitonin (Miacalcic) inj 100 iu per ml, 1 ml – removal of Hospital pharmacy [HP3]-Specialist • Dantrolene sodium (Dantrium) cap 25 mg and 50 mg - removal of Retail pharmacy-Specialist • Glyceryl trinitrate (Lycinate) tab – removal of Section 29 criteria • Isotretinoin (Isotane) cap 10 mg and 20 mg – removal of Specialist prescription and addition of Special Authority • Pamidronate disodium (Pamisol) inj 3 mg per ml, 5 ml; inj 3 mg per ml, 10 ml and inj 6 mg per ml, 10ml – removal of Special Authority criteria • Penicillamine (D-Penamine) tab 125 mg and 250 mg - removal of Retail pharmacy–Specialist • Sodium aurothiomalate (Mycocrisin) inj 10 mg per 0.5 ml; inj 20 mg per 0.5 ml and inj 50 mg per 0.5 ml - removal of Retail pharmacy–Specialist Decreased subsidy (pages 26 – 27) • Allopurinol (Progout) tab 100 mg and 300 mg • Aspirin (Aspec) tab enteric coated 300 mg • Miconazole (Daktarin) oral gel 20 mg per g • Midazolam (Hypnovel and Pfizer) inj 1mg per ml,5 ml and inj 5 mg per ml, 3 ml

Summary of PharmaC decisions – effective 1 march 2009 (continued) increased subsidy (pages 26 – 27) • Bee venom allergy treatment (Albay) maintenance kit and treatment kit 1 OP • Wasp venom allergy treatment (Albay) treatment kit (paper wasp venom) 1 OP • Wasp venom allergy treatment (Albay) treatment kit (yellow jacket venom) 1 OP • Octreotide (Sandostatin) inj 50 µg per ml, 1 ml; inj 100 µg per ml, 1 ml and inj 500 µg per ml, 1 ml

Pharmaceutical Schedule - Update News

Simvastatin tender

As a result of a tender agreement, Arrow-Simva tablets will be listed on the Pharmaceutical Schedule from 1 March 2009 and will become the sole subsidised brand of simvastatin from 1 August 2009. The change to sole supply will include reduced subsidies for Lipex and SimvaRex (from 1 May 2009) and delisting of these brands (from 1 August 2009).

Changes to prescriber restrictions for acitretin and isotretinoin.

PHARMAC is pleased to announce changes to the prescribing restrictions applying to acitretin and isotretinoin. The changes mean that vocationally registered dermatologists, vocationally registered general practitioners, and nurse practitioners working in a relevant scope of practice can now prescribe acitretin and isotretinoin via Special Authority. The Hospital pharmacy [HP3] – Specialist prescription restriction, where the Specialist must be a dermatologist that has applied to acitretin and isotretinoin will be removed from 1 March 2009. They will be replaced by Special Authorities from 1 March 2009 as detailed in pages 21 to 22. Special Authority forms that have already been submitted to the Ministry of Health for approval will be processed before 1 March 2009. Approved applications will be notified to the applicant and patient as soon as possible so that a patient presenting to a pharmacy with a repeat prescription can continue to receive fully subsidised acitretin and isotretinoin. Should a patient present to a pharmacy with a repeat prescription from a dermatologist and not have an approved Special Authority number (e.g. applicant has not applied for one or the patient hasn’t yet received a Special Authority number) there will be a Special Circumstances approval process. This process will be valid for 1 month and will require pharmacies to complete a form (supplied by the Ministry of Health and attached to the Dispatch of the Pharmaceutical Schedule Update) and fax the form to the Ministry of Health for processing (0800 100 131). The Ministry will then contact the pharmacy and advise of the approval number. The intent of the special circumstances approval process is to allow for a smooth transition for current patients only. The Royal New Zealand College of General Practitioners will continue to develop education, assessment and continuing professional development programmes that are relevant to the use of pharmaceuticals, including acitretin and isotretinoin. This will include the accreditation of appropriate learning modules and decision support tools for general practitioners. We also understand that the Royal New Zealand College of General Practitioners will be developing communications to general practitioners to ensure that they are aware of the implications of the changes to the restrictions.

6 Pharmaceutical Schedule - Update News

New 5 second Optium blood glucose test strip

From 1 March 2009 Optium 5 second test strips will be listed fully funded on the Pharmaceutical Schedule. These new blood glucose test strips are compatible with the Optium Xceed blood glucose meters currently funded on the Pharmaceutical Schedule. The new test strips require less blood (0.6uL rather than 1.5uL) and gives quicker results (5 seconds rather than 10 seconds). The Diabetes Subcommittee of PTAC and PTAC have reviewed the new strips. The currently funded 10 second test strips will be delisted from the Pharmaceutical Schedule from 1 September 2009. If you have any further questions, please contact Medica Pacifica directly, on 0800 106 100.

Pantoprazole and Omeprazole injections

From 1 March 2009 pantopraozle 40 mg injection (Pantocid IV) will be listed fully funded on the Pharmaceutical Schedule. This listing provides an alternative proton pump inhibitor parental formulation option for prescribers. Also from 1 March 2009, the Dr Reddy’s Omeprazole brand of omeprazole 40 mg injection will be listed fully funded in the Pharmaceutical Schedule. The Dr Reddy’s Omeprazole brand will become the Sole Subsidised Supply brand of omeprazole injection from 1 May 2009.

Nicotinell gum (nicotine replacement therapy

PHARMAC advised in September 2008 that Nicotinell gum would be delisted in March 2009, however it will now remain listed on the Pharmaceutical Schedule to allow for any claims to be processed for product that might have been purchased during the recent out of stock event for Habitrol gum.

Discontinuation of Minulet and Triphasil

Wyeth Australia has announced the discontinuation of 2 combined oral contraceptives, Minulet and Triphasil. These products are being discontinued from 1 March 2009, delisting will occur later in 2009. For patients switching from Triphasil, Trifeme remains fully funded and Triquilar remains partly subsidised on the schedule for patients requiring a tri-phasic OC. Femodene remains as a partly subsidised ethinyloestradiol with gestodene for patients changing from Femodene.

Pharmaceutical Schedule - Update News

New antiretroviral prescriber:

Dr Emma Best Starship Childrens Hospital (antiretroviral precriber)

Indomethacin discontinuation

Pacific Pharmaceuticals has advised that it is discontinuing supply of all funded strengths of indomethacin capsules and suppositories. There are at present no other registered suppliers in New Zealand. Expected stock run out dates (based on current usage patterns) are: • 25 mg and 50 mg capsules : March/April 2009 • 75 mg long-acting capsules: May 2010 • 100 mg suppositories: early 2012 There are several fully funded alternative Non Steroidal Anti-inflammatory Drugs (NSAIDs) including diclofenac sodium, ibuprofen, naproxen sodium and tenoxicam. PHARMAC has sent a letter to clinicians alerting them to the situation and also advising them that applications for Exceptional Circumstances funding will be considered by PHARMAC for the use of indomethacin in niche indications (chronic paroxysmal hemicrania and hemicrania continua, and reduction of glomerular filtration rate in children being treated for congenital nephrotic syndrome).

Octreotide

As a result of supply issues, PHARMAC has withdrawn sole supply status from the Hospira brand of octreotide injections. From 1 March 2009, both the Hospira and Sandostatin brands of octreotide injection 50 µg per ml, 1 ml, 100 µg per ml, 1 ml and 500 µg per ml, 1 ml will be fully subsidised.

8 Pharmaceutical Schedule - Update News

Important information about diltiazem hydrochloride changes

Due to concerns around prescribing and dispensing errors for diltiazem hydrochloride, there are some changes to the Pharmaceutical Schedule. These include the delisting from 1 June 2009 of: • Dilzem SR 90 mg and 120 mg (twice daily) sustained release capsules • Dilzem LA 180 mg and 240 mg long-acting tablets Please be aware that GPs are changing their patients from the Dilzem preparations to the Cardizem preparations. For those patients who have not yet been changed and will need to be before 1 June 2009, patient information pads have been distributed to pharmacists to give to the patients picking up a prescription for one of the diltiazem preparations that are going to be delisted. To order these patient information pads, please phone the PHARMAC resource line on 0800 11 22 37. Suggested new presentations for diltiazem are: Currently taking Dilzem SR 90 mg capsule (twice daily) Dilzem SR 120 mg capsule (twice daily) Dilzem LA 180 mg tablet (once daily) Dilzem LA 240 mg tablet (once daily) Suggested new presentation Cardizem CD 180 mg capsule (once daily) Cardizem CD 240 mg capsule (once daily) Cardizem CD 180 mg capsule (once daily) Cardizem CD 240 mg capsule (once daily)

Titration to a higher or lower dose may be necessary and should be initiated as clinically warranted

For patients taking Dilzem SR 90 mg or 120 mg once daily (even if it is not the recommended dosing regimen as the blood levels are not maintained above the minimum therapeutic level for 24 hours), we suggest the following: Currently taking Dilzem SR 90 mg capsule (once daily) Dilzem SR 120 mg capsule (once daily) Suggested new presentation Cardizem CD 120 mg capsule (once daily) Cardizem CD 120 mg capsule (once daily)

Those patients may be more likely to experience a change in effect therefore they should be monitored for adverse effects following the change.

tender News

Sole Subsidised Supply changes – effective 1 April 2009

Chemical Name Amoxycillin Amoxycillin Aqueous cream Clotrimazole Ciprofloxacin Presentation; Pack size Oral drops 100mg/ml; 30 ml pack OP Inj 250 mg; 10 pack, 500 mg; 10 pack and 1 g; 10 pack Cream 500 g pot Vaginal crm 2%; 20 g pack OP Tab 250 mg; 30 pack Tab 500 mg; 30 pack and Tab 750 mg; 30 pack Eye drops 0.5%, 15 ml OP Sole Subsidised Supply brand (and supplier) Ospamox (Sandoz) Ibiamox (Douglas) AFT (AFT) Clomazol (Multichem) Rex Medical (Rex Medical)

Hypromellose

Methopt (Sigma)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 april 2009 • Clozapine (Clozaril) tab 25 mg and 100 mg – new listing of 100 tab bottle • Acitretin (Neotigason) cap 10 mg and 25 mg – price and subsidy reduction • Bezafibrate (Bezalip Retard) tab long-acting 400 mg – price and subsidy reduction • Diazepam (Stesolid) rectal tube 5 mg and 10 mg – price and subsidy reduction • Pegylated interferon alpha-2a (Pegasys) pre-filled syringes – a widening of existing subsidised access to include patients with chronic Hepatitis C, genotype 2 and 3 who do not have cirrhosis, and provision of subsidies for patients with chronic hepatitis B

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Acetazolamide Aciclovir Alprazolam

Presentation

Tab 250 mg; 100 tab Tab dispersible 200 mg Tab dispersible 400 mg Tab 250 µg Tab 500 µg Tab 1 mg Inj 10 mg per ml, 1 ml Cap 100 mg Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 100 mg Tab dispersible 300 mg Tab 100 mg Tab 50 mg & 100 mg Eye drops 1%; 15 ml OP Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Inj 1 mega u; 10 inj Scalp app 0.1% Tab 200 mg; 90 tab Tab 50 mg Tab 5 mg Eye drops 0.2% Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Inj 100 iu per ml, 1 ml; 5 inj Cap 0.25 µg & 0.5 µg Tab eff 1 g; 30 tab Inj 50 mg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml

Brand Name Expiry Date*

Diamox Lovir Lovir Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Mayne Symmetrel Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Apo-Ascorbic Acid Ethics Aspirin Ethics Aspirin EC Loten Atropt AstraZeneca AstraZeneca Arrow-Azithromycin Alanase Alanase Sandoz Beta Scalp Fibalip Bicalox Lax-Tab AFT Marcain Isobaric Marcain Heavy ABM ABM Miacalcic Calcitriol-AFT Calsource Calcium Folinate Ebewe Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor 2011 2009 2010

Apomorphine hydrochloride Amantadine hydrochloride Amoxycillin

2009 2011 2010 2009 2009 2010 2009 2011 2009 2009 2009 2011 2009 2011 2011 2010 2011 2010 2009 2011 2009 2011 2011 2010 2010

Ascorbic acid Aspirin Atenolol Atropine sulphate

Azithromycin Beclomethasone dipropionate Benzylpenicillin sodium (Penicillin G) Betamethasone valerate Bezafibrate Bicalutamide Bisacodyl Brimonidine tartrate Bupivicaine hydrochloride Calamine Calcitonin Calcitriol Calcium Calcium folinate Captopril Cefaclor monohydrate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 10

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Cefazolin sodium Cefuroxime sodium Cetomacrogol Chloramphenicol Chlorhexidine gluconate

Presentation

Inj 500 mg Inj 1 g Inj 750 mg & 1.5 g Crm BP Eye drops 0.5% Eye oint 1% Soln 4% Handrub 1% with ethanol 70% Mouthwash 0.2% Tab 25 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05% Tab 500 µg; 100 tab Tab 2 mg; 100 tab Crm 1% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Nasal spray 10 mcg per dose Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Hospira Zinacef PSM Chlorsig Chlorsig Orion Orion Orion Hygroton Klamycin Klacid Dermol Paxam Paxam Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte Nausicalm Cycloblastin Siterone Dantrium Mayne Desmopressin-PH&T Mayne PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit 2011 2011 2010 2009 2011 2009 2009 2010 2009 2011 2011 2010 2010 2010 2010 2010 2010 2009 2010 2009 2009 2010 2011 2009 2010 2011 2010

Chlorthalidone Clarithromycin Clobetasol propionate Clonazepam Clotrimazole Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Desmopressin Dexamethasone sodium phosphate Dexamphetamine sulphate Dextrose Dextrose with electrolytes

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 11

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Diclofenac sodium

Presentation

Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab long-acting 150 mg Tab 2 mg & 4 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Grans for oral liq 200 mg per 5 ml; 100 ml Grans for oral liq 400 mg per 5 ml; 100 ml Tab 10 µg Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Tab 5 mg; 30 tab Inj 250 mg; 10 pack Inj 500 mg; 10 pack Inj 1 g; 10 pack Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 50 mg Cap 150 mg Cap 200 mg Inj 50 mg Tab 10 mg

Brand Name Expiry Date*

Voltaren Ophtha Voltaren Voltaren Voltaren Voltaren Voltaren Apo-Diclo Apo-Diclo SR Videx EC Pytazen SR Apo-Doxazosin AFT m-Enalapril Mayne Cafergot E-Mycin E-Mycin New Zealand Medical and Scientific Brevinor 21 Brevinor 1/21 Brevinor 1/28 Vepesid Ferodan Fintral Flucloxin 2009 2010 2011 2011 2009 2010 2011

2009 2009 2011 2010 2011 2009 2009 2009 2011

Didanosine (DDI) Dipyridamole Doxazosin mesylate Emulsifying ointment Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Erythromycin ethyl succinate

Ethinyloestradiol Ethinyloestradiol with norethisterone

Etoposide Ferrous sulphate Finasteride Flucloxacillin

Flucloxacillin sodium

Staphlex AFT AFT Pacific Pacific Pacific Fludara Fludara

2009

Fluconazole

2011

Fludarabine phosphate

2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 12

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Presentation

Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg TDDS 10 mg Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Crm 1% Tab 5 mg & 20 mg Rectal foam 10%, CFC-Free Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Inj 20 mg, 1 ml Tab 20 mg Oral liq 100 mg per 5 ml, 200 ml Tab 10 mg & 25 mg Tab 2.5 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Inj 50 mg per ml, 2 ml Tab long-acting 60 mg Cap 10 mg Cap 20 mg Cap 100 mg

Brand Name Expiry Date*

Ultraproct Ultraproct 2010

Fluorometholone Fluoxetine hydrochloride Folic Acid Fusidic acid Gentamicin sulphate Gliclazide Glipizide Glyceryl trinitrate

Flucon Fluox Fluox Apo-Folic Acid Foban Pfizer Apo-Gliclazide Minidiab Lycinate Nitrolingual pumpspray Nitroderm TTS 5 Nitroderm TTS 10 Serenace Serenace Serenace AstraZeneca PSM Douglas Colifoam Locoid DP Lotn HC Buscopan Gastrosoothe Fenpaed Tofranil Napamide Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Ferrum H Duride Isotane 10 Isotane 20 Sporanox

2009 2010 2009 2010 2009 2011 2011 2011

Haloperidol

2010 2009 2009 2011 2009 2009 2010 2011 2011 2010 2009 2009 2010

Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Hydrocortisone with wool fat and mineral oil Hysocine N-butylbromide Ibuprofen Imipramine hydrochloride Indapamide Ipratropium bromide

Iron polymaltose Isosorbide mononitrate Isotretinoin Itraconazole

2011 2009 2009 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Ketoconazole Lactulose Levobunolol Levodopa with benserazide

Presentation

Shampoo 2%, 100 ml OP Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Sebizole Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250 Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Ativan Mayne Derbac M A-Lices Ludiomil Colofac Provera Pentasa Arrow-Metformin Methatabs AFT Methotrexate Ebewe Methotrexate Ebewe Methoblastin Prodopa Prodopa Prodopa Rubifen SR Rubifen Rubifen 2009 2010 2010 2010 2011 2010 2010 2009

Lignocaine hydrochloride

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam Magnesium sulphate Malathion Maldison Maprotiline hydrochloride Mebeverine hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate

Tab 1 mg & 2.5 mg Inj 49.3% Liq 0.5% Shampoo 1% Tab 25 mg & 75 mg Tab 135 mg; 90 tab Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 2.5 mg & 10 mg Tab 125 mg; 100 tab Tab 250 mg; 100 tab Tab 500 mg; 100 tab Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg

2009 2009 2010 2010 2009 2011 2010 2009 2009 2010 2009 2011 2009 2011

Methyldopa

Methylphenidate hydrochloride

2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 14

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Methylprednisolone Methylprednisolone aceponate Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol tartrate Metyrapone Miconazole nitrate Midodrine Misoprostol Moclobemide Morphine hydrochloride

Presentation

Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab long-acting 200 mg Cap 250 mg Crm 2% Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg Tab 5 mg Tab 350 µg

Brand Name Expiry Date*

Medrol Advantan Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Slow-Lopresor Metopirone Multichem Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph Mayne Mayne Mayne Mayne m-Eslon Sevredol Mayne Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard Primolut N Noriday 28 2009 2010 2010 2009 2010 2010 2009 2009 2009 2011 2009 2009 2009 2011 2011 2009

2011 2009 2009 2011 2009 2009 2009 2009

Morphine sulphate

2011 2009

Morphine tartrate Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium Neostigmine Nevirapine Nicotinic acid Nifedipine Norethisterone

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 15

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Nortriptyline hydrochloride Nystatin

Presentation

Tab 10 mg; 100 tab Tab 25 mg; 250 tab Oral liq 100,000 u per ml, 24 ml OP Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

Norpress Norpress Nilstat Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Paracare Junior Paracare Double Strength Lacri-Lube Loxamine Permax Permax Pexsig AFT AFT Cilicaine VK Cilicaine VK Prefrin Coloxyl Vistil Vistil Forte Span-K Apo-Prazo 2011 2011 2010 2009 2010 2010 2010 2009

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pamidronate disodium

2011

Pantoprazole

2010

Paracetamol

Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Eye oint with soft white paraffin Tab 20 mg Tab 0.25 mg Tab 1 mg Tab 100 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Oral drops 10%, 30 ml OP Eye drops 1.4% Eye drops 3% Tab long-acting 600 mg Tab 1 mg, 2 mg & 5 mg

2011

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Pergolide Perhexiline maleate Phenoxymethylpenicillin (Penicillin V)

2010 2010 2011 2009 2010

Phenylephrine hydrochloride Poloxamer Polyvinyl alcohol Potassium chloride Prazosin hydrochloride

2010 2011 2011 2009 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 16

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Prednisone

Presentation

Tab 1 mg; 500 tab Tab 2.5 mg; 500 tab Tab 5 mg; 500 tab Tab 20 mg; 500 tab Cassette Inj 1.5 mega u; 5 inj Tab 10 mg Tab 25 mg Tab 50 mg Tab 5 mg; 10 mg & 20 mg Tab 10 mg with hydroclorothiazide 12.5 mg Tab 20 mg with hydroclorothiazide 12.5 mg Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg Tab 150 mg & 300 mg Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Soln 2.3%; 500 ml and 1,000 ml

Brand Name Expiry Date*

Apo-Prednisone Apo-Prednisone Apo-Prednisone Apo-Prednisone MDS Quick Card Cilicaine Allersoothe Apo-Pyridoxine Accupril Accuretic 10 Accuretic 20 Q 200 Q 300 Peptisoothe Mycobutin Arrow-Roxithromycin Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Pinetarsol 2009 2010 2010 2009 2009 2010 2009 2009 2009 2010 2009 2009 2010 2011 2011

Pregnancy tests - HCG urine Procaine penicillin Promethazine Pyridoxine hydrochloride Quinapril Quinapril with hydroclorothiazide

2009 2011 2011 2009 2011 2011

Quinine sulphate Ranitidine hydrochloride Rifabutin Roxithromycin Salbutamol

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Tar with triethanolamine lauryl sulphate and fluorescein sodium Temazepam Terbinafine Testosterone cypionate Tetracosactrin

Tab 10 mg; 25 tab Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 mcg Inj 1 mg per ml, 1 ml

Normison Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot

2011 2011 2011 2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 17

Sole Subsidised Supply Products – cumulative to March 2009

Generic Name

Timolol maleate

Presentation

Eye drops 0.25% Eye drops 0.5% Tab 10 mg Tab 50 mg Crm 0.02%; 100 g OP Oint 0.02%; 100 g OP Inj 40 mg per ml, 1 ml; 5 inj 0.1% in Dental Paste USP Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Tab 300 mg; 50 tab Cap 300 mg Inj 50 mg per ml, 10 ml; 1 inj Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml Ointment BP Cap 220 mg; 100 cap Tab 7.5 mg

Brand Name Expiry Date*

Apo-Timop Apo-Timop Apo-Timol Apo-Thiamine Aristocort Aristocort Kenacort-A40 Oracort Kenacomb 2011 2009 2009 2011 2011 2009

Thiamine hydrochloride Triamcinolone acetonide

Triamcinolone acetonide with gramicidin, neomycin and nystatin Trimethoprim Ursodeoxycholic acid Vancomycin hydrochloride Vincristine sulphate Vitamins Vitamin B complex Water Zinc and castor oil Zinc sulphate Zopiclone March changes in bold type.

TMP Actigall Pacific Mayne Mayne Healtheries Apo-B-Complex Multichem PSM Zincaps Apo-Zopiclone

2011 2011 2011 2009 2009 2009 2009 2011 2011 2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 18

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 March 2009

29 OMEPRAZOLE ❋ Inj 40 mg ................................................................................ 38.20 PANTOPRAZOLE ❋ Inj 40 mg .................................................................................. 8.75 5 ✔ Dr Reddy’s Omeprazole ✔ Pantocid I.V

29 33

GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly Glucose/test strips................................................................... 22.00 50 test OP ✔ Optium 5 second test SIMVASTATIN – see prescribing guidelines on page 49 ❋ Tab 10 mg ................................................................................ 2.05 ❋ Tab 20 mg ................................................................................ 3.00 ❋ Tab 40 mg ................................................................................ 5.35 ❋ Tab 80 mg .............................................................................. 11.65 CILAZAPRIL ❋ Tab 2.5mg ................................................................................ 4.10 ❋ Tab 5 mg .................................................................................. 6.01 MEBENDAZOLE Tab 100 mg ............................................................................ 17.28 90 90 90 90 28 28 24

✔ Arrow-Simva ✔ Arrow-Simva ✔ Arrow-Simva ✔ Arrow-Simva

✔ Inhibace ✔ Inhibace

88 90

✔ De-Worm

AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg – Up to 30 tab available on a PSO ............................................................... 25.10 100 IBUPROFEN ❋ Tab 200 mg ............................................................................ 16.00 1000

✔ Synermox ✔ Ethics Ibuprofen

104

Effective 1 February 2009

73 CONDOMS ❋ 56 mm extra strength - Up to 144 dev available on a PSO ........ 13.36 ❋ 56 mm - Up to 144 dev available on a PSO .............................. 13.36 MEBENDAZOLE – Only on a prescription Tab 100 mg .............................................................................. 2.53 (7.43) TRANYLCYPROMINE SULPHATE Tab 10 mg .............................................................................. 22.94 144 144 ✔ Durex Extra Safe ✔ Durex Select Flavours

4 Vermox 50 ✔ Parnate S29

114

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 January 2009

109 ALLOPURINOL ❋ Tab 100 mg .............................................................................. 5.44 ❋ Tab 300 mg .............................................................................. 4.03 (Note: Progout tabs 100 mg and 300 mg to be delisted 1 June 2009) CLOZAPINE – Hospital pharmacy [HP4] Oral liq 50 mg per ml ............................................................... 34.65 250 100 ✔ Apo-Allopurinol ✔ Apo-Allopurinol

123 184

100 ml

✔ Clopine

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Italian long style spaghetti .......................................................... 2.00 220 g (3.11)

Orgran

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 March 2009

61 63 GLYCERYL TRINITRATE ❋ Tab 600 µg - Up to 100 tab available on a PSO ........................ 8.00 100 OP Lycinate S29

ISOTRETINOIN see Special Authority SA0947 – Hosp pharmacy [HP3]-Specialist prescription Specialist must be a dermatologist Cap 10 mg .............................................................................. 36.00 100 ✔ Isotane 10 Cap 20 mg .............................................................................. 47.50 100 ✔ Isotane 20 ➽ SA0947 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has had an adequate trial on other available treatments and has failed these treatments or these are contraindicated. 2. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice. 3. Patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for acne and the safety issues around isotretinoin and be competent to prescribe it. Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body. Renewal application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following: 1. Patient has had an adequate trial on other available treatments and has failed these treatments or is contraindicated. 2. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant vocational scope of practice. 3. Patient has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for acne and the safety issues around isotretinoin and be competent to prescribe it. Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

ACITRETIN see Special Authority SA0946 – Hosp pharmacy [HP3]-Specialist prescription Specialist must be a dermatologist Cap 10 mg .............................................................................. 94.75 100 ✔ Neotigason Cap 25 mg ............................................................................ 203.70 100 ✔ Neotigason ➽ SA0946 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice. continued... Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2009 (continued)

continued... 2. Patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it. Renewal application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1. Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice. 2. Patient has been counselled and understands the risk of teratogenicity if acitretin is used during pregnancy and the applicant has ensured that, for female patients, the possibility of pregnancy has been excluded prior to the commencement of the treatment and that (where applicable) the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment. Note: Applicants need to have an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and the safety issues around acitretin and be competent to prescribe it. 105 AURANOFIN - Retail pharmacy-Specialist Tab 3 mg ................................................................................ 68.99 (70.97) PENICILLAMINE - Retail pharmacy-Specialist Tab 125 mg ............................................................................ 61.93 Tab 250 mg ............................................................................ 98.98 SODIUM AUROTHIOMALATE - Retail pharmacy-Specialist Inj 10 mg per 0.5 ml ................................................................ 76.87 Inj 20 mg per 0.5 ml .............................................................. 113.17 Inj 50 mg per 0.5 ml .............................................................. 217.23 60 Ridaura 100 100 10 10 10 ✔ D-Penamine ✔ D-Penamine ✔ Myocrisin ✔ Myocrisin ✔ Myocrisin

105

108

ALENDRONATE SODIUM – Special Authority see SA0797948 on the preceding page – Retail pharmacy Tab 70 mg .............................................................................. 35.91 4 ✔ Fosamax Tab 70 mg with cholecalciferol 2800 iu.................................... 35.91 4 ✔ Fosamax Plus ➽ SA07970948 Special Authority for Subsidy Initial application – (Underlying cause - Osteoporosis) only from a relevant specialist or vocationally registered general practitioner from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0. continued...

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2009 (continued)

continued... Initial application – (Underlying cause - glucocorticosteroid therapy) only from a relevant specialist or vocationally registered general practitioner from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months and has either; and 2 Either: 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5); or 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically. Renewal – (Underlying cause was, and remains, glucocorticosteroid therapy) only from a relevant specialist or vocationally registered general practitioner from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents). Renewal – (Underlying cause was glucocorticosteroid therapy but patient now meets the ‘Underlying cause – osteoporosis’ criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mass density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5); or 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or 3 History of two significant osteoporotic fractures demonstrated radiologically; or 4 Documented T-Score ≤ -3.0. Notes: a) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5, and therefore do not require BMD measurement for treatment with bisphosphonates. b) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less. c) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. 108 ALENDRONATE SODIUM – Special Authority see SA0467949 above – Retail pharmacy Tab 40 mg ............................................................................ 133.00 30 ✔ Fosamax ➽ SA0467949 Special Authority for Subsidy Initial Initial application only from any relevant specialist practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Paget's disease; and 2 Any of the following: 2.1 Bone or articular pain; or 2.2 Bone deformity; or continued... ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 March 2009 (continued)

continued... 2.3 Bone, articular or neurological complications; or 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or 2.5 Preparation for orthopaedic surgery. Renewal only from any relevant specialist practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment. CALCITONIN – Hospital pharmacy [HP3]-Specialist ❋ Inj 100 iu per ml, 1 ml ........................................................... 110.00 BACLOFEN - Retail pharmacy-Specialist ❋ Tab 10 mg ................................................................................ 3.75 DANTROLENE SODIUM - Retail pharmacy-Specialist ❋ Cap 25 mg .............................................................................. 32.96 ❋ Cap 50 mg ............................................................................. 51.70 5 100 100 100

108 109 109

✔ Miacalcic

✔ Pacifen ✔ Dantrium ✔ Dantrium

109

PAMIDRONATE DISODIUM – Special Authority see SA0091 below – Hospital pharmacy [HP3] Inj 3 mg per ml, 5 ml ............................................................... 18.75 1 ✔ Pamisol Inj 3 mg per ml, 10 ml ............................................................. 37.50 1 ✔ Pamisol Inj 6 mg per ml, 10 ml ............................................................. 75.00 1 ✔ Pamisol ➽ SA0091 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Either: 1 Paget's disease; or 2 Both: 2.1 Patients under hospice care; and 2.2 Either: 2.2.1 Tumour-induced hypercalcaemia; or 2.2.2 Tumour-induced osteolysis without hypercalcaemia. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Effective 1 February 2009

143 ANASTROZOLE Tab 1 mg – Higher subsidy of $240.00 per 30 with Special Authority see SA0942 ........................................................ 146.46 30 (240.00) Arimidex ➽ SA0942 Special Authority for Alternate Subsidy Initial application - New Patients - only from a relevant specialist. Approvals valid for 5 years for applications meeting the following criteria: All of the following: 1 Patient is a postmenopausal woman; and 2 Patient has hormone receptor positive early breast cancer; and 3 Either: 3.1 The patient has a very clear history of intolerance to tamoxifen; or 3.2 The use of tamoxifen is contraindicated due to a history of thromboembolic disease. continued... Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

S29

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 February 2009 (continued)

continued... Initial application – Patient has had a Special Authority approval for anastrozole prior to 1 December 2008 – only from a relevant specialist. Approval valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. Renewal - only from a relevant specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment. Note: If the patient had an approval for anastrozole prior to 1 December 2008 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. Please phone Ministry of Health Sector Services on 0800 243 666 for clarification if needed.

Effective 1 January 2009

EXTEMPORANEOUSLY COMPOUNDED PRODUCTS AND GALENICALS Standard Formulae 167 MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste .................................................. 275 g Methylhydroxybenzoate ............................................................. 1.5 g Water .................................................................................... 770 ml (Not subsidised as a laxative)

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 March 2009

26 SODIUM ALGINATE ( price) ❋ Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg – peppermint flavour ................. 1.80 (8.60) ❋ Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml (aniseed) ...................................................... 1.50 (8.64) 29 OMEPRAZOLE ( price) ❋ Cap 10 mg ................................................................................ 2.14 (4.40) ❋ Cap 20 mg ................................................................................ 3.05 (4.70) ❋ Cap 40 mg ................................................................................ 3.59 (5.90) ❋ Inj 40 mg .................................................................................. 7.54 (7.73) CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE ( price) ❋ Adhesive gel 8.7% with cetalkonium chloride 0.01 % ................. 2.06 (5.25) MICONAZOLE ( price and subsidy) Oral gel 20 mg per g .................................................................. 8.70 CLOTRIMAZOLE ( price) ❋ Vaginal cream 2% with applicators............................................. 3.44 (5.71) ALLOPURINOL ( subsidy) ❋ Tab 100 mg ............................................................................ 10.88 (11.45) ❋ Tab 300 mg ........................................................................... 20.15 (21.20) ASPIRIN ( subsidy) ❋ Tab EC 300 mg ......................................................................... 2.15 (8.10) DEXTROPROPOXYPHENE WITH PARACETAMOL ( price) Cap hydrochloride 32.5 mg with paracetamol 325 mg.............. 19.91 (33.14) MIDAZOLAM ( price and subsidy) Inj 1 mg per ml, 5 ml ............................................................... 10.75 (14.73) Inj 5 mg per ml, 3 ml ............................................................... 11.90 (19.64) 60 Gaviscon Double Strength 500 ml Gaviscon 30 Losec 30 Losec 30 Losec 1 Losec 15 g OP Bonjela 40 OP 25 g OP Clotrimaderm 2% 500 Progout 500 Progout 100 Aspec 300 500 Capadex 10 10 ✔ Hypnovel Pfizer ✔ Hypnovel Pfizer ✔ Daktarin

37 77

109

110

111

129

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 March 2009 (continued)

129 TRIAZOLAM - Month restriction ( price) Tab 125 µg ............................................................................... 5.10 (6.50) Tab 250 µg ............................................................................... 4.10 (7.20) 100 Hypam 100 Hypam

145

OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA0563 below – Hospital pharmacy [HP3] ( subsidy) Inj 50 µg per ml, 1 ml .............................................................. 43.50 5 ✔ Sandostatin Inj 100 µg per ml, 1 ml ............................................................ 81.00 5 ✔ Sandostatin Inj 500 µg per ml, 1 ml .......................................................... 399.00 5 ✔ Sandostatin BEE VENOM ALLERGY TREATMENT – Special Authority see SA0053 below – Hospital pharmacy [HP3] ( subsidy) Maintenance kit – 6 vials 120 µg freeze dried venom, 6 diluent 1.8 ml............................................. 285.00 1 OP ✔ Albay Treatment kit – 1 vial 550 µg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml ........................................... 285.00 1 OP ✔ Albay WASP VENOM ALLERGY TREATMENT - Special Authority see SA0053 below – Hospital pharmacy [HP3] ( price and subsidy) Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml .............................. 285.00 1 OP ✔ Albay Treatment kit (Yellow jacket venom) – 1 vial 550 µg freeze dried vespula venom, 1 diluent 9 ml , 1 diluent 1.8 ml ............................. 285.00 1 OP ✔ Albay

150

Effective 1 February 2009

27 ZINC OXIDE ( price) Oint zinc oxide with balsam peru ................................................ 4.50 (6.67) Suppos zinc oxide with balsam peru .......................................... 4.47 (6.49) AMLODIPINE ( subsidy) ❋ Tab 5 mg .................................................................................. 2.20 ❋ Tab 10 mg ................................................................................ 3.54 50 g OP Anusol 12 Anusol 30 30 ✔ Calvasc ✔ Calvasc

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN ( price) Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Only on a prescription............ 3.49 15 g OP (6.60) AQUEOUS ( price) ❋ Crm........................................................................................... 2.28 UREA ( price) ❋ Crm 10% ................................................................................... 2.52 (3.07) 500 g 100 g OP

Viaderm KC ✔ Multichem

68 68

Nutraplus

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 February 2009 (continued)

114 TRIMIPRAMINE MALEATE ( subsidy and price) Cap 25 mg ................................................................................ 6.20 Cap 50 mg .............................................................................. 11.20 ANASTROZOLE ( price) Tab 1 mg .............................................................................. 146.46 CETIRIZINE HYDROCHLORIDE ( subsidy) ❋ Tab 10 mg ................................................................................ 1.99 (3.32) ❋ Oral liq 1 mg per ml ................................................................... 1.75 (2.75) 100 100 30 90 Razene 100 ml OP Allerid C ✔ Tripress ✔ Tripress ✔ Arimidex

143 150

Effective 1 January 2009

29 OMEPRAZOLE ( subsidy and  price) ❋ Cap 10 mg ................................................................................ 2.14 (8.43) ❋ Cap 20 mg ................................................................................ 3.05 (9.00) ❋ Cap 40 mg ................................................................................ 3.59 (11.25) NIFEDIPINE ( subsidy and price) ❋ Tab long-acting 30 mg ............................................................ 10.70 ❋ Tab long-acting 60 mg ........................................................... 15.35 68 AQUEOUS CREAM ( subsidy) ❋ Crm........................................................................................... 2.28 (2.37) CLOTRIMAZOLE ( subsidy) ❋ Vaginal crm 2% with applicators ................................................ 3.44 (3.99) AMOXYCILLIN ( subsidy) Drops 125 mg per 1.25 ml ........................................................ 2.67 (7.25) Inj 250 mg ................................................................................ 6.21 (6.32) Inj 500 mg ................................................................................ 7.12 (7.32) Inj 1 g ..................................................................................... 10.8 (11.00) 30 Losec 30 Losec 30 Losec 30 30 ✔ Arrow-Nifedipine XR ✔ Adefin XL ✔ Arrow-Nifedipine XR ✔ Adefin XL

500 g Multichem 25 g OP Clotrimaderm 2% 20 ml OP Amoxil Paediatric Drops 5 Ibiamox 5 Ibiamox 5 Ibiamox

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 January 2009 (continued)

91 CIPROFLOXACIN ( subsidy) Tab 250 mg – Up to 5 tab available on a PSO ............................ 3.13 Tab 500 mg – Up to 5 tab available on a PSO ............................ 4.57 (8.31) Tab 750 mg – Up to 5 tab available on a PSO ............................ 7.04 PYRIDOSTIGMINE BROMIDE ( subsidy) ▲ Tab 60 mg .............................................................................. 40.08 PARACETAMOL ( price) Tab 500 mg - Up to 30 available on a PSO ................................. 1.38 (14.67) 137.81 (1,467.00) CITALOPRAM HYDROBROMIDE ( subsidy) ❋ Tab 20 mg ................................................................................ 1.26 (3.50) 119 120 123 METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL ( subsidy) Tab 5 mg with paracetamol 500 mg........................................... 6.77 60 28 28 28 100 150 Panadol 15,000 Panadol 28 ✔ Cipflox Cipflox ✔ Cipflox

104 110

✔ Mestinon

114

✔ Arrow-Citalopram ✔ Citalopram-Rex Celapram

✔ Paramax

HYOSCINE (SCOPOLAMINE) – Special Authority see SA0727 – Hospital Pharmacy [HP3] ( subsidy) Patches 1.5 mg ....................................................................... 11.95 2 ✔ Scopoderm TTS CLOZAPINE – Hospital pharmacy [HP4] ( subsidy) Tab 25 mg .............................................................................. 13.37 13.37 26.74 Tab 50 mg .............................................................................. 17.33 34.65 Tab 100 mg ............................................................................ 34.65 34.65 69.30 Tab 200 mg ............................................................................ 55.45 110.90 50 50 100 50 100 50 50 100 50 100 ✔ Clopine ✔ Clozaril ✔ Clopine ✔ Clopine ✔ Clopine ✔ Clozaril ✔ Clopine ✔ Clopine ✔ Clopine ✔ Clopine

136

OXALIPLATIN – PCT only – Specialist – Special Authority see SA0900 ( subsidy and price) Inj 50 mg .............................................................................. 200.00 1 ✔ Eloxatin Inj 100 mg ............................................................................ 400.00 1 ✔ Eloxatin Inj 1 mg for ECP ........................................................................ 4.36 1 mg ✔ Baxter OCTREOTIDE (SOMATOSTATIN ANALOGUE) - Special Authority see SA0563 – Hospital pharmacy [HP3] ( subsidy) Inj 50 µg per ml,1 ml .............................................................. 25.65 (43.50) Inj 100 µg per ml, 1 ml ........................................................... 48.50 (81.00) Inj 500 µg per ml, 1 ml .......................................................... 175.00 (399.00)

146

5 Sandostatin 5 Sandostatin 5 Sandostatin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 January 2009 (continued)

161 184 HYPROMELLOSE ( subsidy) ❋ Eye drops 0.5% ........................................................................ 2.00 15 ml OP ✔ Methopt

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital Pharmacy [HP3] ( price) Buckwheat Spirals ..................................................................... 2.00 250 g OP (3.11) Orgran Corn and Spinach Rigattini......................................................... 2.00 250 g OP (2.92) Orgran Corn and Vegetable Shells ......................................................... 2.00 250 g OP (2.92) Orgran Corn and Vegetable Spirals ........................................................ 2.00 250 g OP (2.92) Orgran Garlic and Parsley Shells ........................................................... 2.00 250 g OP (2.92) Orgran Rice and Corn Garden Herb Pasta .............................................. 2.00 250 g OP (2.92) Orgran Rice and Corn Lasagne Sheets .................................................. 2.00 200 g OP (3.82) Orgran Rice and Corn Macaroni ............................................................ 2.00 250 g OP (2.92) Orgran Rice and Corn Penne ................................................................. 2.00 250 g OP (2.92) Orgran Rice and Maize Pasta Spirals ..................................................... 2.00 250 g OP (2.92) Orgran Rice and Millet Spirals ............................................................... 2.00 250 g OP (3.11) Orgran Rice and corn spaghetti noodles ................................................ 2.00 375 g OP (2.92) Orgran Vegetable and Rice Spirals......................................................... 2.00 250 g OP (2.92) Orgran

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 March 2009

33 GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly Glucose/test strips................................................................... 22.00 50 test OP ✔ Optium ✔ Optium 10 second test

Changes to Description

Effective 1 January 2009

38 CALCIUM Tab eff 1 g (elemental) ............................................................. 6.54 30 ✔ Calsource

Changes to General Rules

Effective 1 February 2009

21 3.4 Original packs, and certain Antibiotics 3.4.2 If a Community Pharmaceutical is the liquid form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more of standard packs of the Community Pharmaceutical, Subsidy will only be made paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the unless the Contractor satisfies the Funder that he or she has not been able to dispense the balance of any the pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. In such cases all of that pack or those packs is eligible for subsidy. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where: (i) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and (ii) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner. Note: For the purposes of audit and compliance it is an act of fraud to claim for a whole pack (which includes a wastage amount) and then dispense the wastage amount for a subsequent prescription.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to PSO

Effective 1 March 2009

GLYCERYL TRINITRATE Tab 600 µg ...................................100

Changes to Sole Subsidised Supply

Effective 1 March 2009

For the list of new Sole Subsidised Supply products effective 1 March 2009 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 10-18.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 March 2009

59 91 VERAPAMIL HYDROCHLORIDE ❋ Tab 40 mg ................................................................................ 4.75 FLUCLOXACILLIN SODIUM Inj 250 mg ............................................................................... 4.50 (4.66) Inj 500 mg ................................................................................ 5.20 (5.45) Inj 1 g ....................................................................................... 7.00 (7.54) 100 5 Flucloxin 5 Flucloxin 5 Flucloxin ✔ Verpamil

174

ORAL FEED 1KCAL/ML – Special Authority see SA0594 on the preceding page – Hospital pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.78 237ml OP ✔ Resource Diabetic

Effective 1 February 2009

160 POLYVINYL ALCOHOL ❋ Eye drops 1.4 % ........................................................................ 2.68 ❋ Eye drops 3 % ........................................................................... 3.75 15 ml OP 15 ml OP ✔ Liquifilm Tears ✔ Liquifilm Forte

Effective 1 January 2009

29 OMEPRAZOLE ❋ Cap 10 mg ................................................................................ 2.14 (5.95) ❋ Cap 20 mg ................................................................................ 3.05 (5.95) ❋ Cap 40 mg ................................................................................ 3.59 (8.84) NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg .............................................................................. 34.90 30 Omezol 30 Omezol 30 Omezol 500 ✔ Norpress

114 184

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital Pharmacy [HP3] Garlic and Parsley spirals .......................................................... 2.00 250 g (2.63)

Orgran

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 April 2009

90 AMOXYCILLIN Drops 125 mg per 1.25 ml ........................................................ 2.67 (7.25) Inj 250 mg ............................................................................... 6.21 (6.32) Inj 500 mg ................................................................................ 7.12 (7.23) Inj 1 g – Up to 5 inj available ona PSO...................................... 10.81 (11.00) 114 CITALOPRAM HYDROBROMIDE ❋ Tab 20 mg ................................................................................ 1.26 (3.50) 186 PHENYL FREE PASTA – Special Authority see SA0733 – Hospital pharmacy [HP3] Macaroni ................................................................................. 10.65 500 g OP (11.91) 20 ml OP Amoxil Paediatric Drops 5 Ibiamox 5 Ibiamox 5 Ibiamox 28

✔ Arrow-Citalopram ✔ Citalopram-Rex Celapram

Loprofin

Effective 1 May 2009

53 DOXAZOSIN MESYLATE ❋ Tab 2 mg ................................................................................. 4.81 Note – the 500 tablet pack listed 1 November 2008 OESTRADIOL VALERATE – See prescribing guideline ❋ Tab 2 mg ................................................................................. 4.12 100 ✔ Apo-Doxazosin

✔ Progynova

Effective 1 June 2009

53 DOXAZOSIN MESYLATE ❋ Tab 4 mg .................................................................................. 6.37 Note – the 500 tablet pack listed 1 December 2008 ALLOPURINOL Tab 100 mg ............................................................................ 10.88 (11.45) Tab 300 mg ............................................................................ 20.15 (21.20) CARBAMAZEPINE ❋ Tab 200 mg ........................................................................ 29.06 Note – the 100 tablet pack size listed 1 December 2008 100 ✔ Apo-Doxazosin

109

500 Progout 500 Progout 200 ✔ Tegretol

115

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 July 2009

48 WATER 1) on a prescription or Practitioner’s Supply order only when on the same form as an injection listed in the Pharmaceutical Schedule requiring a solvent or diluent; or 2) on a bulk supply order; or 3) When used in the extemporaneous compounding of eye drops Purified for inj 2 ml – Up to 5 ink available on a PSO ................ 21.90 50 ✔ Baxter CROTAMITON a) Only on a prescription b) Not in combination Lotn 10% .................................................................................. 7.56 (7.70) FLUOROURACIL SODIUM Inj 25 mg per ml, 20 ml – PCT only – Specialist ....................... 55.60

50 ml Eurax 10 ✔ Mayne

136 177

PAEDIATRIC ORAL FEED 1.5KCAL/ML –Special Authority see SA0986 – Hospital pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.27 200 ml OP ✔ Resource Just for Kids Liquid (vanilla)........................................................................... 1.27 200 ml OP ✔ Resource Just for Kids GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Corn and Parsley fettucine ......................................................... 2.00 250 g OP (2.63)

184

Orgran

Effective 1 August 2009

45 48 51 MENADIONE SODIUM BISULPHITE ❋ Tab 10 mg ................................................................................ 4.75 HEPARINISED SALINE ❋ Inj 100 iu per ml, 2 ml ............................................................... 8.30 SIMVASTATIN ❋ Tab 10 mg ................................................................................ 1.27 8.33 ❋ Tab 20 mg ................................................................................ 1.54 10.13 ❋ Tab 40 mg ................................................................................ 2.74 18.00 ❋ Tabs 80 mg............................................................................... 3.18 21.00 MEBENDAZOLE Tab 100 mg .............................................................................. 3.79 (7.59) 100 10 30 30 30 30 ✔ K-Thrombin ✔ Hospira S29 ✔ SimvaRex ✔ Lipex ✔ SimvaRex ✔ Lipex ✔ SimvaRex ✔ Lipex ✔ SimvaRex ✔ Lipex

6 Vermox

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 August 2009 (continued)

104 174 IBUPROFEN ❋ Tab 200 mg .............................................................................. 1.78 100 ✔ I-Profen

ORAL FEED 1KCAL/ML –Special Authority see SA0594 – Hospital Pharmacy [HP3] Liquid (chocolate) ..................................................................... 1.78 237 ml OP ✔ Resource Diabetic

Effective 1 September 2009

33 GLUCOSE DEHYDROGENASE The number of test strips available on a prescription is restricted to 50 unless: 1) Prescribed with insulin or a sulphonylurea but are on a different prescription and prescription is endorsed accordingly; or 2) Prescribed on the same prescription as insulin or a sulphonylurea in which case the Prescription is deemed to be endorsed; or 3) Prescribed for a pregnant woman with diabetes and endorsed accordingly; Blood/glucose test strips ......................................................... 22.00 50 test OP ✔ Optium 10 second test GLYCEROL ❋ Suppos 2.55 g – Only on a prescription ..................................... 3.12 LABETALOL ❋ Inj 5 mg per ml, 5 ml ............................................................... 14.77 (22.15) 12 ✔ Fleet Glycerin Suppositories

Trandate S29

TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 µg per g – Omly on a prescription........... 3.00 15 g OP ETHINYLOESTRADIOL WITH GESTODENE ❋ Tab 30 µg with gestodene 75 µg and 7 inert tab ........................ 6.62 (16.50) ETHINYLOESTRADIOL WITH LEVONORGESTREL ❋ Tab ethinyloestradiol 30 µg with levonorgestrel 50 µg (6) and tab ethinyloestradiol 40 µg with levonorgestrel 75 µg (5), and tab ethinyloestradiol 30 µg with levonorgestrel 125 µg (10) and 7 inert tab ......................................................................... 6.62 (14.49) TRIAMCINOLONE ACETONIDE Inj 10 mg per ml, 1 ml ............................................................. 11.11 DICLOXACILLIN Cap 250 mg .............................................................................. 2.47 (4.35) Cap 500 mg .............................................................................. 3.83 (8.65) 84

✔ Kenacomb

Minulet 28

84 Triphasil 28 5 24 Diclocil 24 Diclocil ✔ Kenacort-A

80 90

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 September 2009 (continued)

174 DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA0594 on the preceding page – Hospital pharmacy [HP3] Liquid ........................................................................................ 7.50 1,000 ml OP ✔ Resource Diabetic TF RTH

Effective 1 October 2009

53 CILAZAPRIL Tab 2.5 mg ............................................................................... 4.39 Tab 5 mg .................................................................................. 6.44 30 30 ✔ Inhibace ✔ Inhibace

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 March 2009

AMOXYCILLIN CLAVULANATE (new listing) Tab amoxycillin 500 mg with potassium clavulanate 125 mg ...Synermox 25.10 100 1% Augmentin Note – the Augmentin brand of amoxycillin clavulanate tablets will be delisted from 1 May 2009

May-2009

CILAZAPRIL (new listing) Tab 2 .5 mg....................................Inhibace 4.10 28 Tab 5 mg........................................Inhibace 6.01 28 Note – the 30 tab pack of Inhibace brand of cilazapril tabs 2.5 mg and 5 mg will be delisted from 1 April 2009 FILGRASTIM (new listing and HSS) Inj 300 µg per 0.5 ml prefilled syringe..........................Neupogen Inj 300 µg per 1 ml vial...................Neupogen Inj 480 µg per 0.5 ml prefilled syringe..........................Neupogen GLYCERYL TRINITRATE (addition of HSS) Tab 600 µg ....................................Lycinate MEBENDAZOLE (new listing and HSS) Tab 10 mg......................................De-Worm MIDAZOLAM ( price) Inj 1 mg per ml, 5 ml .....................Hypnovel Inj 5 mg per ml, 3 ml ......................Hypnovel

135.00 650.00 216.00 8.00 17.28 10.75 11.90

1 5 1 100 OP 24 10 5

1% 1% 1% 1% 1% 5% 5%

Jun-09 Jun-09 Jun-09 Mar-09 Vermox Apr-06 Apr-06

(B) (B) (B) (B) May-2009 Mayne Mayne

OCTREOTIDE (SOMATOSTATIN ANALOGUE) (removal of HSS) Inj 50 µg per ml, 1 ml .....................Hospira 25.65 5 1% Jan-09 Sandostatin Inj 100 µg per ml, 1 ml ...................Hospira 48.50 5 1% Jan-09 Sandostatin Inj 500 µg per ml, 1 ml ..................Hospira 175.00 5 1% Jan-09 Sandostatin Note – Sandostatin inj 50 µg per ml, 1 ml; 100 µg per ml; and 500 µg per ml, 1ml to be delisted 1 January 2009 OMEPRAZOLE ( price) Cap 10 mg .....................................Losec Cap 20mg ......................................Losec Cap 40 mg .....................................Losec Inj 40 mg per 10 ml, vial .................Losec Inf 40 mg .......................................Losec IV OMEPRAZOLE (new listing) Inj 40 mg........................................Dr Reddy’s Omeprazole 4.40 4.70 5.90 7.73 38.65 30 30 30 1 5

38.20

5 5 1 1% Somac May-2009

PACLITAXEL (new pack size) Inj 30 mg........................................Paclitaxel Ebewe 189.75 PANTOPRAZOLE (new listing and HSS) Inj 40 mg .......................................Pantocid Products with Hospital Supply Status (HSS) are in bold. 8.75

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II – effective 1 March 2009 (continued)

PEGFILGRASTIM (new listing) Inj 6 mg per 0.6 ml prefilled syringe..........................Neulastim SIMVASTATIN Tab 10 mg......................................Arow-Simva

1,395 2.05

1 90 1% May-2009

Lipex SimvaRex Tab 20 mg......................................Arow-Simva 3.00 90 1% May-2009 Lipex SimvaRex Tab 40 mg......................................Arow-Simva 5.35 90 1% May-2009 Lipex SimvaRex Tab 80 mg......................................Arow-Simva 11.65 90 1% May-2009 Lipex SimvaRex Note: the SimvaRex brand of simvastatin tabs 10mg, 20mg, 40 mg and 80 mg will be delisted from 1 May 2009

Effective 1 February 2009

AMOXYCILLIN WITH CLAVULANIC ACID ( price) Inj 600 mg, 500 mg with 100 mg clavulanic acid ..............Augmentin Inj 1.2 g, 1000 mg with 200 mg clavulanic acid ..............Augmentin FENTANYL ( price) Inj 50 µg per ml, 2 ml .....................Hospira Inj 50 µg per ml, 10 ml ...................Hospira ZOPICLONE Tab 7.5 mg.....................................Apo-Zopiclone Note: DV date amended from Jan-09 to Feb-09

28.24 31.60 6.10 15.65 21.02

10 10 5 5 500 1% Feb-09 Imovane

Effective 1 January 2009

ALLOPURINOL (new listing and HSS) Tab 100 mg ...................................Apo-Allopurinol Tab 300 mg....................................Apo-Allopurinol 5.44 4.03 250 100 1% 1% Mar-09 Mar-09 Allohexal Allorin Progout Allohexal Allorin Progout

(Note: Progout 100 mg and 300 mg to be delisted 1 March 2009) CLOZAPINE (new listing) Oral liq 50 mg per ml .....................Clopine 45.60 100 ml

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II – effective 1 January 2009 (continued)

CLOZAPINE ( price) Tab 25 mg......................................Clozaril Clopine Clopine Tab 50 mg......................................Clopine Clopine Tab 100 mg....................................Clozaril Clopine Clopine Tab 200 mg....................................Clopine Clopine HYOSCINE (SCOPOLAMINE) (new listing) Patches 1.5 mg .............................Scopoderm TTS HYPROMELLOSE (new listing and HSS) Eye drops 0.5% ..............................Methopt 13.37 26.74 17.33 34.65 34.65 69.30 55.45 110.90 11.95 2.00 50 100 50 100 50 100 50 100 2 15 ml 30 30 1% Mar-09 (B)

NIFEDIPINE ( price) Tab long-acting 30 mg....................Arrow-Nifedipine XR10.70 Adefin XL Tab long-acting 60 mg....................Arrow-Nifedipine XR15.35 Adefin XL OMEPRAZOLE (new listing) Inf 40 mg ......................................Dr Reddy’s Omeprazole 38.65

OMEPRAZOLE ( price) Cap 10 mg .....................................Losec 8.43 30 Cap 20 mg .....................................Losec 9.00 30 Cap 40 mg .....................................Losec 11.25 30 (Note: Losec 10 mg, 20 mg and 40 mg to be delisted 1 May 2009) OXALIPLATIN ( price) Inj 50 mg........................................Eloxatin Inj 100 mg......................................Eloxatin 200.00 400.00 1 1

Effective 1 December 2008

ADRENALINE (new listing) Inj 1,000, 1 ml ................................Aspen-Adrenaline AMISULPRIDE (new listing) Tab 100 mg....................................Solian Tab 200 mg....................................Solian Tab 400 mg....................................Solian Oral liquid 100 mg per ml ...............Solian 4.98 22.52 97.03 185.44 55.44 5 30 60 60 60 ml

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II – effective 1 December 2008 (continued)

AMLODIPINE (new listing) Tab 5 mg........................................Apo-Amlodipine 7.33 100 100 1% 1% Feb-09 Feb-09 Calvasc Norvasc Calvasc Norvasc

Tab 10 mg......................................Apo-Amlodipine 11.79 ANASTROZOLE-DP (new listing) Tab 1 mg........................................DP-Anastrozole CEFAZOLIN SODIUM (delisting) Inj 500 mg......................................m-Cefazolin Inj 1 g.............................................m-Cefazolin CETIRIZINE HYDROCHLORIDE (new listing) Tab 10 mg......................................Zetop

29.50 13.60 18.60 2.21

30 10 10 100 1% Feb-09 Apo-Cetirizine Allerid-C Cetirizine Histaclear Razene Allerid-C Zyrtec

Oral Liquid 1 mg per 1 ml ..............Cetirizine-AFT Note – Allerid-C to be delisted 1 Feb 2009 DILTIAZEM HYDROCHLORIDE (new listing) Tab 30 mg......................................Dilzem Tab 60 mg......................................Dilzem Cap long-acting 120 mg .................Cardizem CD Cap long-acting 180 mg .................Cardizem CD Cap long-acting 240 mg .................Cardizem CD

3.50

200 ml

Feb-09

4.50 8.50 4.72 7.08 9.44

100 100 30 30 30

5% 5% 5% 5% 5% 1%

Jun-09 Jun-09 Jun-09 Jun-09 Jun-09 Jan-09

(B) (B) (B) Dilzem LA Dilzem LA Dosan

DOXAZOSIN MESYLATE (new listing) Tab 4 mg........................................Apo-Doxazosin 30.26 500 Note – Apo-Doxazosin tab 4 mg 100 tablet pack size to be delisted 1 Feb 2009 ERYTHROPOIETIN BETA (price change) Inj 1,000 iu, pre-filled syringe..........Recormon Inj 2,000 iu, pre-filled syringe..........Recormon Inj 3,000 iu, pre-filled syringe..........Recormon Inj 4,000 iu, pre-filled syringe..........Recormon Inj 5,000 iu, pre-filled syringe..........Recormon Inj 6,000 iu, pre-filled syringe..........Recormon Inj 10,000 iu, pre-filled syringe........Recormon FLUOROURACIL SODIUM (new listing) Crm 5% ..........................................Efudix POTASSIUM CHLORIDE (delisting) Inj 75 mg per ml, 10 ml ..................AstraZeneca Inj 150 mg per ml, 10 ml ................AstraZeneca 48.68 120.18 166.87 193.13 243.26 291.92 395.18 26.49 26.00 26.00 6 6 6 6 6 6 6 20 g 50 50

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Chemical and presentation

Brand

Section H changes to Part IV

Effective 1 March 2009

FILGRASTIM Inj 480 µg per 0.5 ml prefilled syringe Neupogen Indefinite supply for any appropriate indication for the management of patients with cancer METHOXSALEN Tab 10 mg Methoxypsaralen Indefinite supply for PUVA – psoralen plus untra violet a (UVA) therapy for severe, disabling psoriasis prephototherapy

Effective 1 December 2008

SPECIAL FOOD SUPPLEMENT Liquid, 237 ml Impact Advanced Recovery Vanilla and Chocolate Three packs of 237 mls per days for 5 to 7 days prior to major gastrointestinal or head or neck surgery.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Acitretin ............................................................. 21 Albay ................................................................. 27 Adefin XL ..................................................... 28, 40 Adrenaline.......................................................... 40 Alendronate sodium ..................................... 22, 23 Allerid C ............................................................. 28 Allopurinol........................................ 20, 26, 34, 39 Amisulpride........................................................ 40 Amlodipine................................................... 27, 41 Amoxil Paediatric Drops ............................... 28, 34 Amoxycillin .................................................. 28, 34 Amoxycillin clavulanate ................................ 19, 38 Amoxycillin with clavulanic acid ......................... 39 Anastrozole .................................................. 24, 28 Anastrozole-DP .................................................. 41 Anusol ............................................................... 27 Apo-Allopurinol ............................................ 20, 39 Apo-Amlodipine ................................................. 41 Apo-Doxazosin............................................. 34, 41 Apo-Zopiclone.................................................... 39 Aqueous ............................................................ 27 Aqueous cream .................................................. 28 Arimidex ...................................................... 24, 28 Arow-Simva ....................................................... 39 Arrow-Citalopram ......................................... 29, 34 Arrow-Nifedipine XR ..................................... 28, 40 Arrow-Simva ...................................................... 19 Aspec 300 ......................................................... 26 Aspen-Adrenaline ............................................... 40 Aspirin ............................................................... 26 Augmentin ......................................................... 39 Auranofin ........................................................... 22 B Baclofen ............................................................ 24 Bee venom allergy treatment .............................. 27 Bonjela .............................................................. 26 C Calcitonin........................................................... 24 Calcium ............................................................. 31 Calsource .......................................................... 31 Calvasc.............................................................. 27 Capadex............................................................. 26 Carbamazepine .................................................. 34 Cardizem CD ...................................................... 41 Cefazolin sodium ............................................... 41 Celapram ..................................................... 29, 34 Cetirizine-AFT..................................................... 41 Cetirizine hydrochloride ................................ 28, 41 Choline salicylate with cetalkonium chloride........ 26 Cilazapril ................................................ 19, 37, 38 Cipflox ............................................................... 29 Ciprofloxacin ...................................................... 29 Citalopram hydrobromide ............................. 29, 34 Citalopram-Rex ............................................ 29, 34 Clopine ............................................ 20, 29, 39, 40 Clotrimaderm 2% ......................................... 26, 28 Clotrimazole ................................................. 26, 28 Clozapine ......................................... 20, 29, 39, 40 Clozaril ........................................................ 29, 40 Condoms ........................................................... 19 Crotamiton ......................................................... 35 D D-Penamine ....................................................... 22 Daktarin ............................................................. 26 Dantrium ............................................................ 24 Dantrolene sodium ............................................. 24 De-Worm ..................................................... 19, 38 Dextropropoxyphene with paracetamol ............... 26 Diabetic enteral feed 1kcal/ml ............................. 37 Diclocil .............................................................. 36 Dicloxacillin........................................................ 36 Diltiazem hydrochloride ...................................... 41 Dilzem ............................................................... 41 Doxazosin mesylate .................................... 34, 41 DP-Anastrozole .................................................. 41 Dr Reddy’s Omeprazole.......................... 19, 38, 40 Durex Extra Safe................................................. 19 Durex Select Flavours ......................................... 19 E Efudix ................................................................ 41 Eloxatin ........................................................ 29, 40 Erythropoietin beta ............................................. 41 Ethics Ibuprofen ................................................. 19 Ethinyloestradiol with gestodene ......................... 36 Ethinyloestradiol with levonorgestrel ................... 36 Eurax ................................................................. 35 F Fentanyl ............................................................. 39 Filgrastim ..................................................... 38, 42 Fleet Glycerin Suppositories ............................... 36 Flucloxacillin sodium .......................................... 33 Flucloxin ............................................................ 33 Fluorouracil sodium...................................... 35, 41 Fosamax ...................................................... 22, 23 Fosamax Plus .................................................... 22 G Gaviscon ........................................................... 26 Gaviscon Double Strength .................................. 26 Glucose dehydrogenase ......................... 19, 31, 36 Gluten free pasta .............................. 20, 30, 33, 35 Glycerol ............................................................. 36 Glyceryl trinitrate .................................... 21, 32, 38

Index

Pharmaceuticals and brands H Heparinised saline .............................................. 35 Hyoscine (scopolamine)............................... 29, 40 Hypam ............................................................... 27 Hypnovel ..................................................... 26, 38 Hypromellose............................................... 30, 40 I Ibiamox........................................................ 28, 34 Ibuprofen ..................................................... 19, 36 Impact Advanced Recovery Vanilla and Chocolate 42 Inhibace ................................................. 19, 37, 38 I-Profen ............................................................. 36 Isotane 10.......................................................... 21 Isotane 20.......................................................... 21 Isotretinoin ......................................................... 21 K Kenacomb ......................................................... 36 Kenacort-A......................................................... 36 K-Thrombin........................................................ 35 L Labetalol ............................................................ 36 Lipex.................................................................. 35 Liquifilm Forte .................................................... 33 Liquifilm Tears ................................................... 33 Loprofin ............................................................. 34 Losec .............................................. 26, 28, 38, 40 Losec IV ............................................................ 38 Lycinate ....................................................... 21, 38 M m-Cefazolin ....................................................... 41 Mebendazole.......................................... 19, 35, 38 Menadione sodium bisulphite ............................. 35 Methopt ....................................................... 30, 40 Methoxypsaralen ................................................ 42 Metoclopramide hydrochloride with paracetamol 29 Magnesium hydroxide mixture ............................ 25 Mestinon............................................................ 29 Methoxsalen ...................................................... 42 Miacalcic ........................................................... 24 Miconazole ........................................................ 26 Midazolam ................................................... 26, 38 Minulet 28.......................................................... 36 Myocrisin........................................................... 22 N Neotigason ........................................................ 21 Neulastim .......................................................... 39 Neupogen .................................................... 38, 42 Nifedipine..................................................... 28, 40 Norpress ............................................................ 33 Nortriptyline hydrochloride.................................. 33 Nutraplus ........................................................... 27 O Octreotide (somatostatin analogue) ........ 27, 29, 38 Oestradiol valerate.............................................. 34 Omeprazole.......................... 19, 26, 28, 33, 38, 40 Omezol .............................................................. 33 Optium............................................................... 31 Optium 5 second test ......................................... 19 Optium 10 second test ................................. 31, 36 Oral feed 1kcal/ml ........................................ 33, 36 Orgran ............................................. 20, 30, 33, 35 Oxaliplatin .................................................... 29, 40 P Pacifen .............................................................. 24 Paclitaxel ........................................................... 38 Paclitaxel Ebewe ................................................ 38 Paediatric oral feed 1.5kcal/ml............................ 35 Pamidronate disodium ....................................... 24 Pamisol ............................................................. 24 Panadol ............................................................. 29 Pantocid ............................................................ 38 Pantocid I.V ....................................................... 19 Pantoprazole ................................................ 19, 38 Paracetamol....................................................... 29 Paramax ............................................................ 29 Parnate .............................................................. 19 Pegfilgrastim ...................................................... 39 Penicillamine...................................................... 22 Phenyl free pasta ............................................... 34 Polyvinyl alcohol ................................................ 33 Potassium chloride ............................................ 41 Progout........................................................ 26, 34 Progynova ......................................................... 34 Pyridostigmine bromide...................................... 29 R Razene .............................................................. 28 Recormon .......................................................... 41 Resource Diabetic ........................................ 33, 36 Resource Diabetic TF RTH.................................. 37 Resource Just for Kids ....................................... 35 Ridaura .............................................................. 22 S Sandostatin .................................................. 27, 29 Scopoderm TTS ........................................... 29, 40 SimvaRex .......................................................... 35 Simvastatin ............................................ 19, 35, 39 Sodium alginate ................................................. 26 Sodium aurothiomalate ...................................... 22 Solian ................................................................ 40 Special food supplement .................................... 42 Synermox .................................................... 19, 38

Index

Pharmaceuticals and brands T Tegretol ............................................................. Trandate ............................................................ Tranylcypromine sulphate .................................. Triamcinolone acetonide .................................... Triamcinolone acetonide with gramicidin, neomycin and nystatin .................................... Triazolam ........................................................... Trimipramine maleate ......................................... Triphasil 28 ........................................................ Tripress ............................................................. U Urea................................................................... 34 36 19 36 27 27 28 36 28 27 V Verapamil hydrochloride ..................................... 33 Vermox ........................................................ 19, 35 Verpamil ............................................................ 33 Viaderm KC........................................................ 27 W Wasp venom allergy treatment ........................... 27 Water ................................................................. 35 Z Zetop ................................................................. 41 Zinc oxide .......................................................... 27 Zopiclone ........................................................... 39

Pharmaceutical Management Agency Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 March 2009

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 March 2009 Cumulative for January, February and March 2009 Section H cumulative for December 2008 and January, February and March 2009. Contents Summary of PHARMAC decisions effective 1 March 2009…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.